Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute report a discovery that helps scientists understand why some tumors lack immune cell infiltration and are therefore unresponsive to newer PD-1 targeted therapies.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
